HDL Diagnostics is a Milwaukee biotechnology company focused on providing the first scalable high-density lipoprotein or HDL function test. HDL is commonly known as the “good cholesterol.” Recent research has established that HDL function testing outperforms HDL-Cholesterol (HDL-C), which simply determines the level of HDL in blood, for predicting heart attacks. HDL function testing measures whether and to what extent the good cholesterol is removing bad cholesterol, or LDL, from the artery walls.
“Testing HDL’s functional status has been available to scientists for years as a research-use-only test, but because of its complexity it is not been used at the point of care,” said board member Matt Amman. “We believe we can change that and improve the ability of physicians to diagnose coronary artery disease with our technology platform.”
Brightstar’s $75,000 investment helped the company complete its second round of funding and start its first clinical trial. The company also recruited Roger Newton, Ph.D., who is the co-discoverer of Lipitor, to join the company’s board of directors.